PharVision Advisers’s Linde LIN Stock Holding History

PharVision Advisers’s Portfolio LIN Stock Details LIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-469	Closed	-$218K	–	363
2025 Q1	$218K	Buy	+469	New	+$211K	0.3%	171

Other funds holding LIN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PharVision Advisers's LIN Position: Q2 2025 in Review

PharVision Advisers sold out of Linde (LIN) in Q2 2025, closing a stake of 469 shares — an estimated $218K sold.

PharVision Advisers first reported a position in LIN in Q1 2025 and held it in 1 quarter. The position peaked at $218K in Q1 2025. 2,101 funds tracked by Wall St. Rank hold LIN as of Q2 2025.

PharVision Advisers reported no remaining Linde position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 469 Linde shares in Q2 2025, an estimated $218K.
PharVision Advisers first reported a position in Linde in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Linde position peaked at $218K in Q1 2025.
2,101 funds tracked by Wall St. Rank held Linde as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.